Before joining Recursion, Rich was an Associate General Counsel at Amgen, where he worked for twenty years, leading a small molecule team that supported five products (Sensipar®, Parsabiv®, Kyprolis®, Otezla®, Lumakras®) and also lead all biologic and small molecule licensing/M&A due diligence projects, including IP lead and IP negotiator on Onyx®, deCODE® and Otezla® acquisitions, and BeiGene collaboration. Prior to Amgen, Rich worked three years at Astra-Zeneca.Rich completed his Ph.D. in organic chemistry at the University of Nevada, followed by an NIH post-doc at Columbia University under Prof. Koji Nakanishi. Koji was not happy when Rich “turned to the dark side” and went on to earn his law degree at Southern Methodist University.After work, Rich enjoys trail running, skiing, sports and theater photography, woodworking, and playing music (piano, guitar, bass).
